- Home
- AVTX vs PHAR Comparison
AVTX vs PHAR Comparison
Compare AVTX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | PHAR |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.7M | 1.0B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVTX | PHAR |
|---|---|---|
| Price | $18.82 | $13.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $40.57 | $38.33 |
| AVG Volume (30 Days) | ★ 1.9M | 5.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $6.21 | $9.54 |
| 52 Week High | $24.27 | $21.34 |
Technical Indicators
Market Signals| Indicator | AVTX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 43.70 |
| Support Level | $13.13 | $12.88 |
| Resistance Level | $19.06 | $13.61 |
| Average True Range (ATR) | 1.33 | 0.46 |
| MACD | -0.13 | -0.08 |
| Stochastic Oscillator | 48.39 | 14.18 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
About PHAR Pharming Group N.V.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.